Shares of genomics company Pacific Biosciences of California jumped 9.9% in the afternoon session after EpiSign Inc. and Geneyx Genomex Ltd. announced a partnership to integrate genomic and epigenomic analysis for rare disease interpretation, incorporating data from PacBio HiFi sequencing. The partnership combines DNA methylation episignature analysis with genomic and multi-omics capabilities to advance rare-disease interpretation. Through the agreement, EpiSign METRIC 5-base extends automated episignature analysis for over 300 disorders to Geneyx customers analyzing DNA methylation data produced by PacBio HiFi, Illumina 5-base, and Oxford Nanopore sequencing. After the initial pop, the shares cooled down and closed the day at $2.88, up 15% from the previous close. PacBio is up 56.5% since the beginning of the year, and at $2.88 per share, it has set a new 52-week high.
Pacific Biosciences of CaliforniaEpiSign-Geneyx partnership will incorporate PacBio HiFi sequencing data for rare-disease episignature analysis, expanding use of PacBio's platform.
Illumina Inc
Oxford Nanopore Technologies Ltd